AGI-14100

• Description :

  AGI-14100 is a metabolically stable and orally available mIDH1 inhibitor (IC50=6 nM) . The pharmacochemical optimization of AGI-14100 is aimed at eliminating hPXR activation, resulting in the final drug candidate AG-120. AG-120 can be used in the study of cancers carrying IDH1 mutations. The discovery and development of AGI-14100 can be used for further studies of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitors[1].

• UNSPSC :

  12352005

• Target :

  Isocitrate Dehydrogenase (IDH)

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/agi-14100.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C([C@@H](N1C2=NC=CC(C#N)=C2)CCC1=O)N([C@@H](C3=CC=CC=C3Cl)C(NC4CC(C4)(F)F)=O)C5=CC(F)=CC(F)=C5

• Molecular Formula :

  C29H22ClF4N5O3

• Molecular Weight :

  599.96

• References & Citations :

  [1]Popovici-Muller J, et al. Discovery of AG-120 (Ivosidenib) : a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers[J]. ACS medicinal chemistry letters, 2018, 9 (4) : 300-305.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1448346-43-7]